In this CFN interview we speak with Dean Petkanas, CEO of KannaLife Sciences, Inc.
KannaLife Sciences, Inc. (“KannaLife”), is a bio-pharmaceutical and phyto-medical company involved in the research and development of novel new therapeutic agents designed to reduce oxidative stress, and act as immuno-modulators and neuroprotectants. KannaLife Sciences currently holds an exclusive license with National Institutes of Health – Office of Technology Transfer (“NIH-OTT”) for the Commercialization of U.S. Patent #6630507, “Cannabinoids as Antioxidants and Neuroprotectants” (the “‘507 Patent”). KannaLife is currently conducting research and development at the Bucks County Pennsylvania Biotechnology Center in Doylestown, PA, for a target drug candidate to treat Hepatic Encephalopathy (“HE”) and Chronic Traumatic Encephalopathy (“CTE”). HE and CTE are both oxidative stress related diseases that affects the cognitive and behavioral functions, and the wellness of the brain.
We were created to develop natural, phyto-medical products to be used in health and wellness regimens. We are also involved in the research and development of novel new therapeutic agents to be used as transport carriers for other compounds seeking to break the blood/brain barrier as well as our own compounds to be used for the treatment and prevention of oxidative and neuro-toxic stresses born from a variety of ailments and illnesses.
KannaLife’s unique approach to drug development combines traditional healthcare practices utilizing natural medicine with western technology to create its pipeline of potential drug candidates for clinical development. Traditional healthcare dates back over 5,000 years, and, according to the World Health Organization, is the primary source of preventative medicine in approximately 80% of the world today.
The scientific team, comprised of dedicated professionals, clinicians and bio-chemists, all have a strong background in phyto-pharmaceutical, biological and Ayurvedic sciences with a long track record of successfully developing drugs from plant sources that are complex in nature and structure. The team also has the requisite relationships with nationally supported institutions of health as well as top academic food and science departments at several recognized universities in the United States.
KannaLife depends on the sustainability of plant life to create its products and practices environmentally sound business practices. Our ultimate goal is to become a profitable and socially responsible company that seeks to improve the quality of life of patients needing and using our products.
Dean Petkanas – Chairman & CEO Dean Petkanas is a corporate finance executive management professional with over 25 years of investment banking and capital markets experience. He specializes in structured merchant banking and corporate financing centered on “Distressed-to-Control” or “Loan-to-Own” strategies (pre-packaged bankruptcies – 1145 exchanges); “Start Ups”, “Turnarounds” for companies undergoing operational or financial challenges.
For the past two decades Mr. Petkanas was responsible for and involved in over 100 public and private corporate finance transactions, including merchant banking, IPOs, Registered Direct, PIPEs, EXIM guarantees, mergers and acquisitions, totaling approximately $500 million in financings.
Most recently Mr. Petkanas was hired by Xechem International (a publicly traded biotech company) to assist in the commercialization of Nicosan/Hemoxin, a phyto-pharmaceutical compound for the treatment of Sickle Cell disease. Commercialization efforts were for Orphan Drug approval (Hemoxin) in the United States and construction of pharmaceutical manufacturing of Nicosan in Nigeria.
While at Xechem, he was the lead petitioner for Xechem International in steering their federal anti-trust lawsuit against Bristol-Myers-Squibb for their illegal monopoly of the drug market for the anti-cancer drug, Taxol®. Mr. Petkanas’ extensive has also been involved in several hydrocarbon and petrochemical projects. He was involved in the financing, creation and operation of Nuecol Corp., which became the parent and successor in interest to Coal Technology Corporation (CTC), a company that held patented technology in the agglomeration of char, gasification of coal derived fuels and briquetting of agglomerated char into form coke.
In his position as the Director and V.P. of Business Development for Nuecol Corp. Mr. Petkanas raised financing of approximately $13 million for the Carbo, VA project facility to manufacture 500,000 tons of CTC form coke annually.
In addition to the several board memberships that Mr. Petkanas has held throughout his career, he is currently on the board of Full Motion Beverage, Inc., a publicly traded, specialty beverage company. He serves as a director of Prosperity Systems, Inc., a privately held cloud computing and software services company, and Tire International Environmental Solutions.
Follow Us on Social Media
About CFN Media
CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.
CFN launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across North America. Today, CFN Media is also the digital media choice for the emerging brands in the space.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: http://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer.
Disclaimer: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/.